RedHotStocks

ZYMEWORKS IS ON THE HOT BIO STOCK LIST FOR 2019

NYSE:ZYME   None
Despite a 75% move in 2019 there is still plenty of room to run, indicators are still not oversold and volume remains very high.
Momentum shows no sign of slowing down
Continual upside call buying in the option market.
Promising trial data expected in cancer fighting Drug program.
Moving averages are perfectly formed and fanning out as strength continues.


AVERAGE ANALYSTS PRICE TARGET $28
AVERAGE ANALYSTS RECOMMENDATION BUY


COMPANY PROFILE
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

면책사항

이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.